Objective: To obtain a reliable estimate of the magnitude of the prospective association between gamma-glutamyltransferase (GGT) and risk of hypertension, and to characterize the nature of the dose-response relationship. Methods: We conducted a systematic review and dose-response meta-analysis of published prospective studies. Relevant studies were identified in a literature search of MEDLINE, EMBASE, and Web of Science databases up to May 2015. Study specific relative risks (RRs)
INTRODUCTION
Hypertension or high blood pressure (BP) has risen to pandemic proportions -affecting over 1 billion people worldwide and it has been estimated that this number will reach 1.56 billion by 2025. [1] In addition to being the leading global risk for mortality in the world, [2] hypertension is the most common modifiable and leading risk factor for cardiovascular disease (CVD), [3] which represents a worldwide epidemic and is the leading cause of mortality globally. [4] To date, established risk factors for hypertension include excess body weight, excess dietary sodium intake, reduced physical activity, and excess alcohol intake. [5, 6] In line with the 2013 guidelines developed by the European Society of Hypertension and the European Society of Cardiology (ESH/ESC), [7] lifestyle changes have been recommended as the cornerstone for the prevention of hypertension or high BP. These include a combination of population-based and intensive targeted approaches such as reduction of salt and alcohol consumption, maintaining a healthy body weight, regular exercise, and elimination of smoking. [7] Though established risk factors for hypertension explain a large proportion of its risk, its pathogenesis is still not fully established as multiple factors appear to be involved. There is therefore a need to further assess potential risk factors which may have causal or predictive relevance to hypertension and which will help further tailor preventive and therapeutic interventions Gamma-glutamyltransferase (GGT), a sensitive but non-specific index of liver injury and a biological clue of excessive alcohol intake, has been strongly linked to the development of adverse cardiometabolic outcomes [8] [9] [10] including hypertension. [11] Elevated serum levels of GGT has been postulated to reflect the development and progression of hepatic steatosis; which may play an important role in the development of insulin resistance and hyperinsulinemia, resulting in high blood pressure or hypertension. [12] [13] [14] Until recently, there has been uncertainty regarding the magnitude and nature of the prospective association between GGT level and risk of hypertension. Liu and colleagues [15] synthesized available prospective epidemiological data on the association between GGT and hypertension and reported a pooled multivariate adjusted relative risk (RR) (95% confidence interval) of 1.94 (1.55-2.43) for hypertension in a comparison of top versus bottom category of baseline GGT levels. However, in this review, the authors did not standardize the reported risk estimates (they reported comparisons comparing the highest versus lowest category of GGT levels irrespective of the risk estimates the eligible studies reported) to a consistent comparison before pooling. In addition, they separately pooled the results of three studies that provided risk estimates per 1 standard deviation (SD) increment in loge GGT levels. Given these, the magnitude of the association could not be precisely determined. In addition, although the evidence suggests there is a strong association between elevated baseline circulating GGT and risk of incident hypertension; characterization of the nature and magnitude of the dose-response relationship is however still lacking, as this was not addressed by previous studies and the recent review. It is uncertain if there is a clear continuous dose-response relationship to the association or if this association is evident only beyond a particular threshold level of GGT. It is important to establish this, especially if there exists a threshold which would potentially optimize the detection of individuals at increased risk of hypertension. A dose-response analysis is more efficient than comparing the highest to lowest category approach, as it uses all of the exposuredisease information and provides a detailed description of the risk of the disease throughout the observed range of the exposure. [16] Against this background, our first objective using a metaanalytic approach, was to obtain a reliable estimate of the magnitude of the association between GGT and hypertension, by including all relevant studies and standardising reported risk estimates from all studies to a consistent comparison (top versus bottom thirds of baseline levels of GGT) before pooling. Our second objective was to quantify and characterize in detail the nature of the dose-response relationship between GGT level and risk of hypertension.
METHODS

Data sources and searches
This systematic review and meta-analysis of studies was conducted using a predefined protocol and reported in accordance with PRISMA and MOOSE guidelines [17, 18] (Supplementary Materials 1-2). We searched MEDLINE, EMBASE, and Web of Science for prospective (cohort, case-cohort or "nested case control") population-based studies that measured the level of enzymatic activity of GGT and evaluated associations between baseline circulating level of GGT with risk of hypertension or high BP up to May 2015. The computer-based searches combined free and MeSH search terms and combined key words related to GGT (e.g., "gamma glutamyltransferase") and hypertension (e.g., "hypertension", "blood pressure"). There were no restrictions on language or the publication date. We scanned the reference lists of retrieved articles for all relevant additional studies and review articles. We restricted the search to studies of humans. Further details on the search strategy are presented in Supplementary Material 3.
Study selection
Observational cohort studies were included if they had at least 1 year of follow-up, assessed associations of GGT with hypertension in adults (>18 years), measured samples at baseline, recruited participants representative of approximately general populations (i.e., did not select participants on the basis of confirmed pre-existing medical conditions such as hypertension or high blood pressure, cardiovascular disease, liver disease, or chronic kidney disease at baseline).
Retrospective studies were not included.
Data extraction and quality assessment
Two authors independently abstracted data and performed quality assessments using a standardized predesigned data collection form. Data were abstracted, where available, on study, publication date, geographical location, population source, time of baseline survey, sample population, study design, sample source (plasma/serum), nature of sample (fresh or frozen and storage temperature), assay type and source, sample size, number of hypertension cases, hypertension case definition, mean age range at start of study, duration of follow-up, and degree of adjustment for potential confounders (defined as '+' when RRs were adjusted for age and/or sex; '++' further adjustment for potential risk factors for hypertension such as body mass index, plasma or serum lipids, smoking status, exercise, or alcohol consumption; and '+++' additional adjustment for other liver enzymes and or inflammatory markers). We extracted RRs reported for the greatest degree of adjustment. In the case of multiple publications involving the same cohort, the most up-to-date study or study with the most comprehensive information was abstracted. We contacted authors of eligible studies where the published data were insufficient, to provide relevant missing information.
Study quality was assessed based on the nine-star Newcastle-Ottawa Scale (NOS) [19] using pre-defined criteria namely: selection (population representativeness), comparability (adjustment for confounders), and ascertainment of outcome. The NOS assigns a maximum of four points for selection, two points for comparability, and three points for outcome. Nine points on the NOS reflects the highest study quality. A score of ≥ 5 indicated adequate quality for inclusion in the review.
Data synthesis and analysis
The RR with 95% CIs was used as the common measure of association across studies. To enable a consistent approach to the meta-analysis and enhance interpretation of the findings, reported study-specific risk estimates (per standard deviation change, quintiles, quartiles, and user-defined cut-offs) were transformed to involve comparisons between the top third and bottom third of each study population's baseline distribution of GGT levels, using standard statistical methods [20, 21] which have been described in detail in Supplementary Material 4.
Briefly, log risk estimates were transformed assuming a normal distribution (or that a transformation of the explanatory variable for which the risk ratio is based was normally distributed), with the comparison between top and bottom thirds being equivalent to 2.18 times the log risk ratio for a 1 standard deviation increase (or equivalently, as 2.18/2.54 times the log risk ratio for a comparison of extreme quarters and as 2.18/2.80 times the log risk ratio for a comparison of extreme quintiles). Standard errors of the log risk estimates were calculated using published confidence limits and were standardised in the same way. When studies published more than one estimate of the association according to subgroups (e.g., by sex), we obtained a within-study summary estimate using a fixed effect meta-analysis. Summary RRs were pooled using a random effects model to minimize the effect of between-study heterogeneity. [22] To avoid making an assumption of linearity for an exposure-response (e.g. GGT-hypertension) relation, exposure-response relations are usually reported through RRs corresponding to ranges of exposure levels. Therefore, in a meta-analysis, it is useful to model the relation in a flexible nonlinear manner and assess evidence for or lack of nonlinearity, using graphical and statistical testing procedures. [23] We therefore performed a 2-stage dose-response meta-analysis using the method proposed by Orsini, [24] to examine a potential nonlinear relationship between GGT levels and hypertension risk by modeling GGT levels using restricted cubic splines with 3 knots at percentiles 25%, 50%, and 75% of the distribution. [25] This method requires that the number of cases, person-years of follow-up or non-cases, and the RRs with the variance estimates for at least three quantitative categories of GGT levels are known. The median or mean level of GGT for each category was assigned to each corresponding RR. If data were not available, we estimated the median using the midpoint of each category. When the highest or lowest category was open, we assumed it to be the same amplitude as the adjacent category. In the first stage, as described by Orsini et al, [24] a restricted cubic spline model with 2 spline transformations (3 knots minus 1) was estimated using generalized least-squares regression taking into account the correlation within each set of published RRs. In the second stage, the 2 regression coefficients and the variance/covariance matrix that had been estimated within each study were combined using the restricted maximum likelihood method in a multivariate random-effects meta-analysis. [26] A P value for nonlinearity was calculated by testing that the coefficient of the second spline was equal to zero. [27] Statistical heterogeneity across studies was quantified using Cochran χ 2 and the I 2 statistics. [28, 29] Study-level characteristics including geographical location, sex, average age at baseline, average duration of follow-up, number of cases, case definition for hypertension, degree of adjustment, and study quality were pre-specified as characteristics for assessment of heterogeneity, which was conducted using stratified analysis and random effects meta- 
RESULTS
Study identification and selection
Our initial search identified 612 potentially relevant citations ( Figure 1) . After screening the titles and abstracts, 23 articles remained for further evaluation. We reviewed and assessed these 23 articles, and excluded 9 articles because (i) they had no relevant outcome (n = 6) (ii) they were not prospective (n = 2) or duplicated a previous publication using the same cohort (n = 1).
In sum, this meta-analysis included 14 articles (Supplementary Material 5) based on 14 unique prospective cohort studies comprising 44,582 participants and 5,270 hypertension cases. Table 1 provides details of the eligible studies. The mean age of participants at baseline ranged from approximately 25 to 62 years. One study included participants aged 15 years and over, however, participants who were less than 18 years comprised only 9.3% of the total sample. [34] Two studies included participants from Europe (France and Turkey), two from North America (United States), nine from Asia (South Korea, Hong Kong, Japan, and China), and one from Australia. Duration of follow-up to the development of hypertension ranged from 3 to 15 years.
Study characteristics and quality
Studies ascertained the diagnosis of hypertension (or high blood pressure) using the following definitions: blood pressure ≥ 130/85 mmHg, 140/90 mmHg, 160/95 mmHg and/or taking antihypertensive medication. All studies evaluated the associations in approximately general healthy populations with the exception of one study which was conducted among prehypertensive adults.
[35] The degree of covariate adjustment varied, but majority of studies adjusted for potential risk factors for hypertension such as age, body mass index, smoking status, exercise, and alcohol consumption, with three additionally adjusting for another liver enzyme or inflammatory markers. Two studies adjusted for only age. An unadjusted estimate was calculated for one study. Overall, we judged all of the included studies to be of adequate quality (quality score: 6-9). One study scored 9 points, four studies scored 8 points, seven studies scored 7 points, and two studies scored 6 points. Supplementary Material 6 provides assay characteristics of measured levels of GGT from studies contributing to the analysis. Apart from 7 studies which did not provide specific details of type of assays used for GGT measurements, all other studies employed the enzymatic colorimetric method which has been shown to be precise for detecting GGT activity.
[36] As reported in Supplementary Material 6, the majority of studies assessed the associations within normal reference ranges of GGT.
Association of GGT and hypertension
The pooled RR (95% CI) of hypertension in a comparison of individuals in the top thirds with those in the bottom thirds of baseline GGT level for all 14 studies was 1.32 (1.23-1.43) ( Figure   2 ). The combined RR excluding the study which was conducted among participants with prehypertension was 1.31 (1.22-1.42), which was similar to the main finding. Similarly, the pooled RR was 1.26 (1.18-1.35) on excluding the study with an unadjusted estimate and 1.30 (1.21-1.40) on excluding the study that included participants aged 15 years and over. The pooled RR was minimally attenuated on simultaneously excluding all three studies 1.23 (1.15-1.31). On simultaneous exclusion of the study with an unadjusted estimate and studies that presented only age-adjusted estimates, the pooled RR was attenuated but not significantly altered 1.08 (1.02-1.13). There was substantial heterogeneity between studies (I 2 >70%), which was partly explained by study level characteristics such as age at baseline (P for meta-regression = 0.007), average follow-up duration (P for meta-regression = 0.04), and degree of adjustment (P for meta-regression < 0.0001) (Supplementary Material 7). A stronger association was observed in studies that included older participants (≥ 45 years) compared to studies with younger participants (< 45 years) and studies with a longer duration of follow-up (≥ 5 years) compared to studies with shorter duration of follow-up (< 5 years). In further subgroup analysis (data not shown), a stronger association was observed in Asian studies 2.16 (1.47-3.19) compared to other populations 1.53 (1.12-2.10) (P for meta-regression = 0.293). Egger's test was significant (P = 0.001), consistent with observed funnel plot asymmetry (Supplementary Material 8), suggesting that studies with less striking results were less likely to have been reported. Despite the concern that small studies with null results often tend not to be published, we found no definitive evidence of such selective reporting when studies were grouped by size in meta-regression analysis (Supplementary Material 7). Duval and Tweedie's trim-and-fill method identified 7 missing studies and addition of these hypothetical missing studies did not alter the significant association between GGT and hypertension risk, although substantially weaker (pooled RR comparing top versus bottom third, 1.11: 1.02-1.20).
Dose-response analysis
In pooled analysis of 10 studies (total of 13 data points because results for males and females were reported separately for some of the studies) providing relevant data, we found no evidence of statistically significant departure from linearity (P for nonlinearity =0.37) between GGT levels and risk of hypertension, which was present across the spectrum of GGT values (4.5-54.5 U/L) in our study. Visual inspection of the plot was also consistent with a linear shape ( Figure   3 ). The combined RR (95% CI) of hypertension for a 5 U/L increment in GGT level was 1.08 (1.04-1.13).
DISCUSSION
Unlike the previous elegant review by Liu adjustment. There were more extreme results in studies conducted among older individuals, consistent with established evidence that increasing age is associated with a significant increase in the incidence of hypertension or high BP. As expected, a stronger association with longer follow-up duration was also demonstrated. A stronger association was observed in Asian populations compared to Western populations (though P-value for meta-regression > 0.05), consistent with findings from the previous review [15] and the fact that liver diseases and metabolic syndrome (strongly associated with hypertension or high BP) are very prevalent in Asians. A stronger association was also observed in males compared to females (though P-value for meta-regression > 0.05); which is consistent with the significant gender differences in GGT levels, with males having higher levels than females.
[37] In addition, males are more likely to develop cardiometabolic diseases at lower average levels of risk markers such as body mass index, [38] which is also causally associated with GGT levels.
[39] However, in the context of the greater proportion of studies featuring more male than female participants in our review, these findings should be interpreted with caution. Our study also provides for the first time, a detailed assessment of the dose-response nature of the association between circulating GGT level and risk of hypertension. The findings were consistent with a linear dose-response relationship, which was characterised by an 8% increase in the risk of hypertension for every 5 U/L increment in circulating GGT level.
Possible explanations for findings
A large body of evidence has shown that GGT is positively and independently associated with Elevated GGT levels are also suggested to signify oxidative stress and a state of chronic inflammation.
[43] The states of oxidative stress, increased inflammation, and fatty liver may impair insulin signalling in the liver, leading to impaired insulin secretion and insulin resistance, which have been implicated in the development of hypertension or high BP. [12, 14] Implications of findings Our findings are relevant as they provide further insight concerning the relationship between baseline circulating GGT levels and risk of hypertension and may also have implications for the prevention of hypertension or high BP. Though the cut-off value and reference range for GGT has not been clearly defined, and is essentially arbitrary, being determined ideally by enzyme measuring activity in a healthy population and using the central 95% of values obtained from the population;[44] the recommended cut-off for the upper normal limit of GGT is set at an average of 51 U/L for men and 33 U/L for women.
[45] Consistent with the large body of evidence suggesting an increased risk of adverse cardiometabolic outcomes at GGT levels considered to reflect normal reference ranges, [8, 9, 40] our findings also underscore a potentially deleterious role of increasing GGT levels within the normal range on future risk of hypertension in general population settings. Lifestyle measures such as salt restriction, moderation of alcohol consumption, high consumption of vegetables and fruits and low-fat, maintaining a healthy body weight, regular physical exercise, and elimination of smoking been recommended as the cornerstone for the prevention of hypertension in non-hypertensive individuals. [7] Given that serum GGT levels can be considerably reduced by most of these lifestyle interventions, [46] which also affect levels of established risk factors for hypertension;
there remains a possibility that lowering or modification of serum levels of GGT may help in hypertension prediction or prevention. Further evaluation is warranted.
Strengths and limitations
The strengths and limitations of this meta-analysis merit careful consideration. The notable strengths include our ability to transform reported risk estimates from all contributing studies to a consistent comparison (top versus bottom thirds) to allow a consistent combination of estimates across studies, therefore obtaining a reliable estimate of the magnitude of the association and enhancing interpretation of the overall findings. We have also provided a detailed assessment of the dose-response relationship between GGT and risk of hypertension, which has not been previously demonstrated. We systematically explored and identified the possible sources of heterogeneity using stratified analyses and meta-regression. Formal tests demonstrated evidence of publication bias, suggesting that studies with less striking results were less likely to have been reported. However, there was no clear evidence of such selective reporting when studies were grouped by size. A detailed quality assessment of eligible studies was performed, with all included studies attaining moderate to high quality scores. Our main weakness was the inability to fully examine the impact of adjustment for potential confounding factors, because the review was based on variably adjusted data reported in the published literature. However, majority of included studies adjusted for major potential confounders (including alcohol consumption which is known to increase serum levels of GGT) of the GGThypertension association and grouping the studies by degree of adjustment did not appreciably alter the direction of the association. In addition, the dose-response analysis was based on data points from ten out of the 14 eligible studies, as the investigators concerned did not respond to our request for additional data or could not be contacted at all. Finally, it was not possible to correct the estimates for within-individual variation in levels of GGT, because the included studies lacked serial assessments of circulating levels of this exposure in the same individuals.
Conclusions
Circulating level of GGT is associated with an increased risk of hypertension in the general population, consistent with a linear dose-response relationship. Further investigation of any potential relevance of GGT in hypertension prevention is warranted.
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